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EFFECT OF HOMELESSNESS AND EVER-IVDU ON  
HEPATITIS C LINKAGE TO CARE 
HEATHER FOSS 
ABSTRACT 
It has been widely shown that intravenous drug use (IVDU) is a major risk factor 
for Hepatitis C Virus (HCV), and Hepatitis C remains highly prevalent among homeless 
populations. More data is needed to demonstrate the effectiveness of linkage to care and 
treatment programs within these high risk populations. Determining the social and 
clinical risk factors associated with lower rates of positive HCV clinical outcomes such as 
linkage and treatment can have a significant impact on patient outcomes and public 
health program success.   
A prospective cohort of 1254 subjects was used for these analyses. Log binomial 
regression models were created for the analysis of both homelessness and whether the 
patient has ever injected drugs (ever-IVDU) separately for their associations with linkage 
to HCV care. 
 The cohort was 68% male and 32% female, with median age of 44 years old 
(range 18-90 years old). Thirty-five percent of the study population was inside the “baby 
boomer” birth cohort (born 1945-1965) which is considered to be a particularly high risk 
population. Four percent of the population was co-infected with Hepatitis B Virus and 6% 
were co-infected with HIV. Sixty-two percent of the cohort reported homelessness, and 
78% had ever used IV drugs. Homeless individuals had an adjusted RR of 0.82 (95% CI: 
0.70-0.91) and patients having ever used IV drugs had an adjusted RR of 1.06 (95% CI: 
 v 
0.94–1.19) for the outcome of HCV linkage to care. 
The results of this study showed that homeless individuals had an 18% decreased 
risk of becoming linked to care compared to those that are not homeless, while ever-
IVDU showed no significant association with linkage to care after controlling for 
confounding. 
With Hepatitis C being so prevalent among homeless populations, these results 
are especially helpful in informing linkage to care programs. Understanding the major 
barriers to care that these patients face is crucial to designing linkage and navigation 
programs that will successfully engage and benefit these patients. 
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Introduction 
 Hepatitis C Virus (HCV) infection has been found to be highly prevalent in the 
United States, with an estimated 3.5 million people suffering from the disease1–3. 
Approximately ½ to ⅔ of patients infected with HCV develop a chronic infection, 
defined as detectable viremia ≥ six months after initial infection. Chronic HCV plays a 
significant role in the development of hepatocellular carcinoma, the development of 
cirrhosis and is a leading cause of liver disease-related deaths nationwide2. Patients with 
chronic HCV infection are often asymptomatic and approximately 50% of patients in the 
United States with chronic HCV are unaware of their infection3. There are multiple 
barriers impeding diagnosis and successful treatment. Systemic problems include the 
difficulty of screening patients, the cost of current treatment [$83,000–$153,000 USD], 
and restrictive health plan policies. Individual patient factors include lack of ability to 
obtain follow up RNA testing and co-morbid medical, substance use, psychiatric, and 
social issues4–6.  
 The cascade of HCV care from diagnosis through cure has been described at 
length in the literature7–9. Although there are different variations of the cascade, it 
generally involves making the initial diagnosis, confirming the diagnosis, disclosing the 
diagnosis to the patient, and linking the patient to HCV medical care for disease staging, 
treatment initiation, treatment completion, and testing for sustained virologic response 
(SVR). Decades of HIV research have provided invaluable knowledge regarding this type 
of cascade of care, and this knowledge can be extrapolated and applied to HCV 
management10.
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 Prior to 2014 only about half of patients treated with antiviral therapies for HCV 
would achieve SVR7. Newer therapies, including the direct-acting antiviral (DAA)-
containing regimens, have demonstrated SVR rates greater than 80 percent. The SVR 
rates exceed 90 percent when interferon-free combination treatment regimens are 
included7,8. Several current treatments for HCV are agnostic to HCV genotype or active 
against specific genotypes and are considered curative11,12. Curing HCV results in 
decreased transmission, and decreased morbidity and mortality13,14. 
 Due to the effectiveness of these new treatment regimens, both the U.S. Centers 
for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force 
(USPSTF) endorsed guidance for routine one-time HCV Antibody (Ab) screening for 
individuals born from 1945 to 1965 (the “birth cohort”) as well as continued targeted 
testing for injection drug users (IDUs) and others at high risk for HCV infection15. 
 Determining the social and clinical risk factors that are associated with lower rates 
of positive HCV clinical outcomes can have a significant impact on patient outcomes and 
public health program success. Hepatitis C remains highly prevalent among homeless 
populations, and more research is still needed to demonstrate the effectiveness of linkage 
and treatment programs within these populations16. By determining the factors that are 
associated with lower rates of positive HCV outcomes, public health programs can be 
better informed and more able to tailor their outreach and treatment efforts to meet the 
unique needs of varied patient populations in an effort to bring the communities closer to 
HCV elimination. 
 
3 
 
Setting 
Boston Medical Center (BMC) is an urban, academic facility that receives 
approximately 1,150,000 patient visits per year. The medical center is recognized as the 
primary “safety net” provider of care for the city’s indigent and most vulnerable 
population. In the medical center, more than 70% of patients identify as minority; more 
than 50% identify as African American; and more than 20% identify as Hispanic/Latino. 
Approximately 25% of BMC patients are homeless. 
 BMC has developed an HCV screening program which was implemented in 
November 2016. This program has been used in conjunction with the medical center’s 
hospital-wide linkage, outreach, and treatment efforts. Its objective has been to increase 
diagnosis of HCV and HCV linkage to care in the institution. The first step was to 
implement reflex testing for HCV RNA and genotyping for all specimens identified as 
HCV Ab seropositive. This removed the added obstacle of bringing in Ab+ patients for 
follow-up labs. The program was initiated in the Emergency Department (ED), where 
opt-out HCV screening was offered to all ED patients over 13 years of age who were 
undergoing phlebotomy for any clinical purpose. Outpatient sites included clinics in The 
Center for Infectious Diseases (CID), General Internal Medicine (GIM), and Family 
Medicine (FM). In the outpatient clinics, HCV screening was offered to all patients who 
met high risk criteria (born between 1945 and 1965 or documented history of IDU). 
Screening in the ED and all outpatient locations was triggered by utilization of a multi-
purpose best practice advisory (BPA) that fired an alert to the provider that a patient was 
eligible for testing and generated a laboratory order when the provider chose “yes.” 
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Methods 
Study Design 
These analyses were conducted using a cohort of HCV RNA positive patients 
followed prospectively at BMC during the period from July 1, 2016 to January 31, 2019. 
The enrollment period for this study was from July 1, 2016 to July 31, 2018, ending 6 
months prior to the end of the study period. The primary objective of this study was to 
determine the degree to which homelessness and intravenous drug use are associated with 
linkage to HCV care among patients screened in the BMC screening program. 
BMC’s HCV linkage program constructed a relational database for tracking 
patients within the program, and for data management using Salesforce healthcloud 
(Salesforce.com). All hospital HCV Ab tests were downloaded daily. Results from 
patients under 18 years, those tested in a non-study site, and those previously enrolled in 
our navigation program were removed. The remaining patients were assigned study IDs 
and enrolled into Salesforce. The navigators tracked these patients’ charts and updated 
Salesforce with RNA results once received. We populated the database using electronic 
queries of the EMR, manual chart reviews, and direct communications with patients. 
BMC’s HCV testing and linkage project was approved by the Institutional Review Board 
at Boston University Medical Center. It adhered to the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guidelines for cohort studies. IRB 
number H-35734. There was a waiver for informed consent because this was a research 
analysis of a clinical program. It met all criteria for the waiver. 
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 Patient navigators provided active outreach to patients with positive HCV RNA 
results (those with active HCV) to engage patients in HCV care consistently throughout 
the study period. Outreach attempts adhered to standardized guidelines. Navigators 
followed a sequence of four phone calls with voicemails, a call to the emergency contact 
with voicemail, and a mailed letter to the address on file in their medical record. If a 
patient was not able to be contacted by the end of this sequence, they were marked as lost 
to follow up. If a patient was successfully contacted before completing this sequence, the 
navigators maintained contact until the patient was either successfully linked, provided a 
reason that excluded them from being linked to care, or until the navigators lost contact 
and then completed the outreach sequence over from the beginning, starting at the time of 
last communication. Linkage outcomes for these patients were collected from July 1, 
2016 through January 31, 2019. This provided 6 months of time after the last patient was 
enrolled for them to be linked to HCV care. A random sample of 300 linked patients has 
shown that 83% of our linked patients were linked within 3 months of their positive HCV 
test, 92% were linked within 5 months of being tested, and 93% were linked within 6 
months of being tested. 
Participant Identification 
 Enrollment for this analysis was ongoing and started on July 1, 2016.  For the 
purposes of this analysis, data was included on all patients that tested RNA positive for 
Hepatitis C from July 1, 2016 to July 31, 2018 that met the below criteria. There was no 
missing or incomplete data for this study because all required inclusion and demographic 
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information was available within each patient’s chart. If no exclusions listed below were 
found within the patient’s chart, that patient was enrolled into navigation. Patients 
claiming an applicable exclusion to navigation services during outreach attempts were 
updated in the database as being excluded and were removed from navigation. The final 
list of subjects that met all inclusion criteria and that were never found to have any of the 
applicable exclusions below were retained for these analyses. 
Inclusion Criteria 
1. At least 18 years old  
2. Has a Hepatitis C RNA+ lab result from one of the five BMC testing sites for 
which data are collected (Emergency Department, General Internal Medicine, 
Family Medicine, Infectious Diseases, and Inpatient) 
3. Enrolled into patient navigation services 
Exclusion Criteria 
1.  Incarcerated 
2. Terminally ill or deceased 
3. Pregnant 
4. Already in HCV care elsewhere 
5. Moved away from BMC 
6. Previously enrolled into HCV navigational services (if a patient was out of 
care and re-tested, they were not re-enrolled) 
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Primary Exposure and Outcome Variables 
The primary exposure variables for this analysis were homelessness and having 
ever engaged in intravenous drug use (ever-IVDU). Homelessness was a binary (yes, no) 
variable which was determined through patient medical chart review or patient self-report 
at time of HCV antibody test. Ever-IVDU was a binary (yes, no) variable recorded as the 
patient’s history of ever using intravenous drugs, determined through patient medical 
chart review or self-report. 
The outcome variable was linkage to HCV care. This was a binary (yes, no) 
variable defined as those patients that were HCV RNA positive that attended a Hepatitis 
C intake appointment at any point during the study period following their enrollment into 
the study. All patients enrolled into the study conformed to the above inclusion and 
exclusion criteria, and therefore were all eligible for linkage. Patients were marked as 
“linked” by navigators once the patient was known to have arrived to their HCV intake 
appointment per their medical chart. Due to the design of the navigation program, there 
was no missing outcome data. Every linkage at BMC was able to be captured by the 
navigators and those not yet linked were continuously tracked and monitored through 
regular chart reviews. 
Statistical Analyses 
Demographic and clinical characteristics were presented by both homeless status 
and ever-IVDU status using descriptive statistics. Since all characteristics were 
categorical, cross-tabulations with chi-square tests were constructed to determine and test 
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the associations between these variables and both homelessness and ever-IVDU 
separately. Log-binomial regression models were used to determine the unadjusted 
associations between the characteristics and linkage to HCV care. The Breslow-Day test 
was used to assess interaction between homelessness and ever-IVDU in their relationship 
to linkage to HCV care. An alpha level of 0.05 (5%) was used to determine statistical 
significance. No significant interaction was found in this data set, so homelessness and 
ever-IVDU were analyzed separately as primary exposures. 
To determine the adjusted risk ratios for the association between homelessness 
and linkage to care, as well as the association between ever-IVDU and linkage to care, 
log-binomial regression was used. Potential confounders were added to the model for 
homelessness and linkage to care separately and individually.  Any variables found to 
result in a 10% or greater change in the crude measure of effect estimate were retained in 
the model. This process was repeated in a separate model for ever-IVDU and linkage to 
care. Once this was completed for each variable, the final models included all 
confounding variables and the adjusted risk ratios were reported. For all statistical 
analyses, 95% confidence intervals were also used as a measure of statistical stability. All 
statistical analyses were performed in SAS 9.4 (SAS Institute, Cary NC). 
 
Results 
Characterization of Study Sample 
 A cohort of 1,635 subjects was identified through the inclusion criteria. Based on 
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the exclusion criteria, 381 of these patients were excluded, for a final total of 1,254 
subjects. Identified reasons for exclusion were patients already being in HCV care 
elsewhere (68%), terminally ill or deceased (17%), or incarcerated (15%). A descriptive 
analysis was performed on the identified final cohort of 1254 subjects. Patient 
demographic and comorbidity characteristics can be seen in Table 1.  
Confounders and Multivariate Analysis 
 Table 1 also shows the univariate analyses for potential risk factors and their 
relationships with linkage to HCV care. Table 2a displays descriptive characteristics by 
homeless status and their univariate associations with homelessness. Similarly, Table 2b 
shows the descriptive characteristics by ever-IVDU status, and their univariate 
associations with ever-IVDU. There was no significant interaction found between 
homelessness and ever-IVDU in this data set, so they were analyzed separately as 
primary exposures. Potential confounders in both models were defined as those variables 
that were associated with the exposure, were an independent predictor for the outcome, 
and were not on the causal pathway. For the association between homelessness and 
linkage to care, the following variables were identified as potential confounders: ever-
IVDU, age distribution, birth cohort, race, marital status, and testing site. For the 
association between ever-IVDU and linkage to care, the following variables were 
identified as potential confounders: homelessness, age distribution, birth cohort, race, 
marital status, HIV co-infection and testing site. All variables, regardless of whether they 
met the above criteria for potential confounders, were added individually to each of the 
models to check for a 10% change in estimate. This was done as an extra precautionary 
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measure, since all variables used in these analyses have been previously identified in the 
literature as predictors for linkage to care outcomes. 
Table 3a shows the final multivariable model construction for homelessness and 
linkage to care, and displays the change in effect caused by each variable. For this model, 
the only variable retained as a confounder was testing site. Table 3b shows the final 
multivariable model construction for ever-IVDU and linkage to care, and displays the 
change in effect caused by each variable.  For this model, age distribution, race, and 
homelessness were all retained as confounding risk factors. Although baby boomer birth 
cohort also resulted in a change in effect greater than 10%, this variable and age 
distribution are both based on age, so only one of these variables were retained in the 
final model. For this model, age distribution was chosen to be retained due to the greater 
change in estimate for this variable. Homeless individuals had an 18% decrease in risk of 
being linked to HCV care compared to those that were not homeless (RR=0.82, 95% CI: 
0.7-0.91) after being adjusted for confounders. Patients having ever used IV drugs had an 
adjusted RR of 1.06 (95% CI: 0.94-1.19). 
 
Discussion 
 The purpose of this study was to determine if either homelessness or ever-IVDU 
are associated with linkage to HCV care among those that are HCV RNA+. These 
analyses did find an association between homelessness and linkage to care among this 
cohort. Homeless individuals were found to have an 18% decreased risk of becoming 
linked to care compared to those that are not homeless after controlling for confounding. 
11 
 
For ever-IVDU and linkage to care, there was no significant association found in these 
analyses after controlling for confounding. Those that had ever used IV drugs showed an 
insignificant increase in risk of linkage to care versus those that had never used IV drugs.  
 With Hepatitis C being so prevalent among homeless populations, these results 
are especially helpful in informing linkage to care programs. The association between 
homelessness and poor linkage to care outcomes suggests that homelessness is a barrier 
to linkage.  Understanding this is crucial to designing linkage and navigation programs 
that will successfully engage and benefit these patients. Seeing significant barriers such 
as homelessness may suggest the need to provide housing support and other resources to 
homeless patients with HCV prior to being able to engage them in care. It is possible that 
assisting patients in achieving this level of stability in their lives may provide a strong 
foundation on which to add other important public health initiatives, such as regular 
medical and HCV care. The significant effect of testing site on the interaction between 
homelessness and linkage to care highlights the differences in patient populations 
presenting to primary care compared to those presenting and being tested in the ED or 
while inpatient. It is thought that patients tested in the ED were not tested in a primary 
care setting because they don’t attend primary care services (and this theory is consistent 
with the fact that approximately 50% of patients seen in the ED at BMC don’t have a 
primary care provider). It could be that engaging patients in primary care is a potential 
step to consider toward being able to link them to specialized HCV care. 
 A major strength of this study is the wide capture net. This cohort pulls all eligible 
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patients from 28,000 Hepatitis C antibody tests performed at BMC over a 2-year period.  
Boston Medical Center has a very diverse patient population, which allows for increased 
generalizability. The study population has a high proportion of both exposure variables 
and has about 51% of enrolled patients linked to HCV care. Both the exposed and 
unexposed, as well as those with and without the outcome of interest are well-represented 
in this study. 
 One of the biggest limitations of this study is the potential for under-reporting of 
both homelessness and IVDU. Both factors are based on chart reviews and patients’ self-
reports to our navigators. Patients that are either homeless or have a history of IVDU may 
not feel comfortable sharing this information with their medical providers or with patient 
navigators for many different reasons. This exposure misclassification could bias the true 
association between these characteristics and linkage to HCV care toward the null. 
Studies able to look specifically at current IVDU compared to ever-IVDU may find 
different results than those from these analyses, which is another limitation of this study. 
It is also possible for patients to become linked to care outside of BMC without the 
navigation team’s knowledge. Patients are excluded from navigation services once it has 
been verified that they have been linked to care outside of BMC (one of the exclusion 
criteria for the study), but it is possible for them to be linked elsewhere without BMC’s 
knowledge, especially if the patient is never able to be successfully reached by BMC’s 
navigators. These data are also from a single medical center in an inner city with a high 
underlying disease burden, and findings may not be similar at other institutions with 
different populations. 
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As a large safety-net hospital, BMC is very intertwined and involved with the 
surrounding homeless population. The medical center provides a wide variety of 
resources to homeless patients, such as food, housing, and financial support. Because of 
this existing relationship with the community, it could be that the medical center actually 
has greater success linking these patients to care compared to hospitals with less direct 
involvement in homeless communities. If this is the case, other medical centers may see 
even greater disparities in linkage rates between homeless and non-homeless patients. 
 Further studies should be done on homelessness and IVDU as they relate to 
linkage to care. More research conducted to determine and analyze risk factors 
preventing linkage to care among HCV patients will be extremely beneficial to increasing 
linkage and eventually eliminating HCV among these populations. A greater knowledge 
of HCV patient barriers to care will allow programs to be optimally tailored to their 
patients’ needs 
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Table 1. Characteristics of HCV RNA+ patients, linkage to care data, and RR for linkage 
to care 
N= 1254 N (%) Linked to HCV 
Care  
N (%)  
Unadjusted RR (95% CI)  
p-value 
Homeless       
Yes 775 (61.80) 303 (39.10) 0.66 (0.59, 0.74) p<0.0001 
No 479 (38.20) 283 (59.08) Ref 
Ever IVDU       
Yes 977 (77.91) 432 (44.22) 0.80 (0.70, 0.90) p=0.0004 
No 277 (22.09 154 (55.60) Ref 
Sex       
Male 852 (67.94) 414 (48.59) 1.13 (0.99, 1.29) p=0.07 
Female 402 (32.06) 173 (43.03) Ref 
Age Distribution     0.353 (0.61, 2.08) p=0.71 
18-25 51 (4.07) 19 (37.25) - 
26-35 355 (28.31) 117 (32.96) - 
36-45 250 (19.94) 96 (38.40) - 
46-55 253 (20.18) 137 (54.15) - 
56-65 262 (20.89) 166 (63.36) - 
66-75 69 (5.50) 49 (71.01) - 
≥76 14 (1.12) 4 (28.57) - 
In Baby Boomer 
Birth Cohort 
(1945-1965) 
      
Yes 433 (34.53) 269 (62.12) 1.61 (1.44, 1.80) p< 0.0001 
No 821 (65.47) 317 (38.61) Ref 
Race       
Black/ African 
American 
379 (30.22) 236 (62.27) 1.56 (1.32, 1.84) p<0.0001 
White 671 (53.51) 255 (38.00) 0.67 (0.57, 0.79) p<0.0001 
Other 204 (16.27) 95 (46.57)  1.00 (0.80, 1.24) p=0.97 
Hispanic Ethnicity       
Yes 194 (15.47) 98 (50.52) 1.09 (0.94, 1.28) p=0.24 
No 1060 (84.53) 488 (46.04) Ref 
Marital Status       
Single 961 (76.63) 421 (43.81) 0.78 (0.65, 0.93) p=0.01 
Married 105 (8.37) 74 (70.48) 1.58 (1.24, 2.02) p=0.0002 
Other 188 (14.99) 91 (48.40)  1.04 (0.83, 1.30) p=0.72 
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Residence (inside 
Boston) 
      
Yes 827 (65.95) 413 (49.94) 1.23 (1.08, 1.41) p=0.002 
No 427 (34.05) 173 (40.52) Ref 
Hep B Co-
Infection 
      
Yes 45 (3.59) 29 (64.44) 1.40 (1.12, 1.75) p=0.004 
No 1209 (96.41) 557 (46.07) Ref 
HIV Co-Infection       
Yes 71 (5.66) 46 (64.79) 1.42 ( 1.18, 1.70) p=0.0002 
No 1183 (94.34) 540 (45.65) Ref 
HCV Testing Site       
Emergency 
Department 
678 (54.07) 224 (33.04) 0.53 (0.45, 0.62) p<0.0001 
General Internal 
Medicine 
383 (30.54) 267 (69.71) 1.90 (1.62, 2.24) p<0.0001 
Center for 
Infectious Diseases 
44 (3.51) 37 (84.09) 1.85 (1.33, 2.59) p=0.0003 
Family Medicine 35 (2.79) 29 (82.86) 1.81 (1.25, 2.63) p=0.002 
Inpatient 114 (9.09) 29 (25.44) 0.52 (0.36, 0.76) p=0.0006 
 
Table 2a. Characteristics by homelessness status 
Variable 
Not Homeless 
(n=479) Homeless (n=775) 
P-values for 
univariate association 
with homelessness 
Linked to HCV 
Care 283 (59.08) 303 (39.10) <0.0001 
Ever-IVDU 310 (64.72) 667 (86.06) <0.0001 
Male 307 (64.09) 545 (70.32) 0.02 
Age Distribution     <0.0001 
18-25 16 (3.34) 35 (4.52) - 
26-35 103 (21.50) 252 (32.52) - 
36-45 74 (15.45) 176 (22.71) - 
46-55 94 (19.62) 159 (20.52) - 
56-65 129 (26.93) 133 (17.16) - 
66-75 51 (10.65) 18 (2.32) - 
≥76 12 (2.51) 2 (0.26) - 
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In Baby Boomer 
Birth Cohort 
(1945-1965) 
216 (45.09) 217 (28.00) <0.0001 
Race     <0.0001 
Black/ African 
American 185 (38.62) 194 (25.03) - 
White 226 ( 47.18) 445 ( 57.42) - 
Other 68 (14.2) 136 (17.55) - 
Hispanic 
Ethnicity 61 (12.73) 133 (17.16) 0.07 
Marital Status     <0.0001 
Single 335 (69.94) 626 (80.77) - 
Married 68 (14.20) 37 (4.77) - 
Other 76 (15.86) 112 (14.46) - 
Residence (inside 
Boston) 305 (63.67) 522 (67.35) 0.18 
Hep B Co-
Infection 20 (4.18) 25 (3.23) 0.38 
HIV Co-Infection 21 (4.38) 50 (6.45) 0.12 
HCV Testing Site     <0.0001 
Emergency 
Department 204 (42.59) 474 (61.16) - 
General Internal 
Medicine 199 (41.54) 184 (23.74) - 
Center for 
Infectious 
Diseases 
20 (4.18) 24 (3.10) - 
Family Medicine 20(4.18) 15 (1.94) - 
Inpatient 36 (7.52) 78 (10.06) - 
 
Table 2b. Characteristics by ever-IVDU status 
Variable 
Never IVDU 
(n=277) 
Ever IVDU 
(n=977) 
P-values for univariate 
association with ever-
IVDU 
Linked to HCV 
Care 154 (55.60) 432 (44.22) <0.0001 
Homeless 108 (38.99) 667 (68.27) <0.0001 
Male 187 (67.51) 665 (68.07) 0.86 
Age 
Distribution     <0.0001 
18-25 4 (1.44) 47 ( 3.75) - 
26-35 30 (10.83) 325 (33.27) - 
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36-45 26 (9.39) 224 (22.93) - 
46-55 71 (25.63) 182 (18.63) - 
56-65 96 (34.66) 166 (16.99) - 
66-75 39 (14.08) 30 (3.07) - 
≥76 11 (3.97) 3 (0.31) - 
In Baby 
Boomer Birth 
Cohort (1945-
1965) 
169 (61.01) 264 (27.02) <0.0001 
Race     <0.0001 
Black/ African 
American 132 (47.65) 247 (25.28) - 
White 94 (33.94) 577 (59.06) - 
Other 51 (18.41) 153 (15.66) - 
Hispanic 
Ethnicity 38 ( 13.72) 156 ( 15.97) 0.42 
Marital Status     <0.0001 
Single 177 (63.90) 784 (80.25) - 
Married 42 (15.16) 63 (6.45) - 
Other 58 (20.94) 60 (13.30) - 
Residence 
(inside Boston) 192 (69.31) 635 (64.99) 0.18 
Hep B Co-
Infection 6 (2.17) 39 (3.99) 0.15 
HIV Co-
Infection 5 (1.81) 66 (6.76) 0.002 
HCV Testing 
Site     <0.0001 
Emergency 
Department 155 (55.96) 523 (53.53) - 
General Internal 
Medicine 81 (29.24) 302 (30.91) - 
Center for 
Infectious 
Diseases 
5 (1.81) 39 (3.99) - 
Family Medicine 18 (6.50) 17 (1.74) - 
Inpatient 18 (6.50) 96 (9.83) - 
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Table 3a. Final model construction for homelessness and linkage to care. Variables were 
each added separately and individually. Those with a 10% change in estimate were 
retained in the final model. 
Variable Added Estimate Change in Estimate Retained in Model? 
Homelessness 0.6617 -- -- 
Sex 0.6573 0.7% No 
Age Distribution 0.718 8.5% No 
Baby Boomer Birth 
Cohort 0.7063 6.7% No 
Race 0.697 5.3% No 
Hispanic Ethnicity 0.6614 0.0% No 
Marital Status 0.6933 4.8% No 
Residence 0.6579 0.6% No 
Hep B 0.6686 1.0% No 
HIV 0.6683 1.0% No 
Testing Site* 0.8176 24% Yes 
Ever IDU 0.6786 2.6% No 
*Each of the 5 sites were added into the model as yes/no variables. This is the change in estimate 
when controlling for each of the 5 testing sites together. 
 
Table 3b. Final model construction for ever-IVDU and linkage to care. Variables were 
each added separately and individually. Those with a 10% change in estimate were 
retained in the final model. 
Variable Added Estimate Change in Estimate Retained in Model? 
Ever IDU 0.7953 -- -- 
Sex 0.8038 1.7% No 
Age Distribution 0.9916 24.7% Yes 
Baby Boomer Birth 
Cohort 0.9411 18.3% No* 
Race 0.8894 11.8% Yes 
Hispanic Ethnicity 0.7967 0.2% No 
Marital Status 0.8414 5.8% No 
Residence 0.798 0.3% No 
Hep B 0.7936 0.2% No 
HIV 0.7777 2.2% No 
Testing Site** 0.8587 8.0% No 
Homeless 0.8833 11.0% Yes 
*Since Age Distribution and Baby Boomer Birth Cohort are both based on age, only age 
distribution was chosen to be retained due to the greater change in estimate for this variable. 
**Each of the 5 sites were added into the model as yes/no variables. This is the change in 
estimate when controlling for each of the 5 testing sites together.
18 
 
References 
1. Schechter-Perkins, E. M. et al. Implementation and Preliminary Results of an 
Emergency Department Nontargeted, Opt-out Hepatitis C Virus Screening Program. 
Academic Emergency Medicine 25(11), 1216–1226 (2018). doi:10.1111/acem.13484 
2. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA 
recommendations for testing, managing, and treating adults infected with hepatitis C 
virus. Hepatology 62, 932–954 (2015) 
3. Spradling, P. R. et al. Hepatitis B and C virus infection among 1.2 million persons 
with access to care: factors associated with testing and infection prevalence. Clinical 
Infectious Diseases 55, 1047–1055 (2012). 
4. Ward, J. W. & Mermin, J. H. Simple, Effective, but Out of Reach? Public Health 
Implications of HCV Drugs. New England Journal of Medicine 373, 2678–2680 
(2015). 
5. Canary, L. A., Klevens, R. M. & Holmberg, S. D. Limited Access to New Hepatitis C 
Virus Treatment Under State Medicaid Programs. Annals of Internal Medicine 163, 
226–228 (2015). 
6. Younossi, Z. M. et al. Disparate access to treatment regimens in chronic hepatitis C 
patients: data from the TRIO network. Journal of Viral Hepatitis 23, 447–454 (2016). 
7. Maier, M. M., Ross, D. B., Chartier, M., Belperio, P. S. & Backus, L. I. Cascade of 
Care for Hepatitis C Virus Infection Within the US Veterans Health Administration. 
American Journal of Public Health 106, 353–358 (2016) 
8. Linas, B. P. et al. The Hepatitis C Cascade of Care: Identifying Priorities to Improve 
Clinical Outcomes. PLoS ONE 9, e97317 (2014). 
9. Fox, M. P. & Rosen, S. A new cascade of HIV care for the era of ‘treat all’. PLoS 
Medicine 14, e1002268 (2017). 
10. Gardner, E. M., McLees, M. P., Steiner, J. F., Del Rio, C. & Burman, W. J. The 
spectrum of engagement in HIV care and its relevance to test-and-treat strategies for 
prevention of HIV infection. Clinical Infectious Diseases 52, 793–800 (2011). 
11. Swain, M. G. et al. A sustained virologic response is durable in patients with chronic 
hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139, 
1593–1601 (2010). 
 
19 
18 
 
12. Pearlman, B. L. & Traub, N. Sustained virologic response to antiviral therapy for 
chronic hepatitis C virus infection: a cure and so much more. Clinical Infectious 
Diseases 52, 889–900 (2011). 
13. Simmons, B., Saleem, J., Heath, K., Cooke, G. S. & Hill, A. Long-Term Treatment 
Outcomes of Patients Infected With Hepatitis C Virus: A Systematic  Review and 
Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. 
Clinical Infectious Diseases 61(5):730–740 (2015). 
 
14. Review and Meta-analysis of the Survival Benefit of Achieving a Sustained 
Virological Response. Clinical Infectious Diseases 61, 730–740 (2015). 
15. Singal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M. & Schoenfeld, P. S. A 
sustained viral response is associated with reduced liver-related morbidity and 
mortality in patients with hepatitis C virus. Clinical Gastroenterology and 
Hepatology 8, 280–288, 288.e1 (2010). 
16. Hepatitis C Information | Division of Viral Hepatitis | CDC. (2017). Available at: 
https://www.cdc.gov/hepatitis/hcv/index.htm. (Accessed: 30th October 2018) 
17. Philbin MM, Tanner AE, DuVal A, et al. Factors affecting linkage to care and 
engagement in care for newly diagnosed HIV-positive adolescents within fifteen 
adolescent medicine clinics in the United States. AIDS and Behavior 18(8):1501-1510 
(2014). 
 
20
21 
 
Curriculum Vitae 
                                  
18 
 
 
22 
